AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04120649 — intervention group
Intervention type: PROCEDURE
Intervention: hysterectomy
Description: total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
Study NCT06755905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICGL-guided treatment
Description: Indocyanine green lymphography guided resection combined with sclerotherapy
Study NCT03948412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Incision Negative Pressure Wound Therapy (Prevena)
Description: Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
Study NCT03948412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Standard Dressings
Description: Standard wound dressings applied to closed wound at completion of operation.
Study NCT02099617 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent
Study NCT02099617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent
Study NCT02099617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
Study NCT01741688 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tocilizumab
Description: Tocilizumab was administered according to the local label.
Study NCT01323387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Interbody Fusion
Description: allograft spacer + anterior plate
Study NCT02778009 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition
Study NCT02778009 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition
Study NCT02778009 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iDEXA Scan
Description: Subjects will receive pre study and post study scans to assess body mass composition
Study NCT02778009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellness Lectures
Description: Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
Study NCT02778009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
Study NCT02778009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
Study NCT02778009 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
Study NCT03052231 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: caremessage
Description: Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
Study NCT05935397 — intervention group
Intervention type: DEVICE
Intervention: percutaneous coronary intervention
Description: patients with CAD undergoing PCI with second generation DES
Study NCT06755905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment group
Description: Resection with sclerotherapy
Study NCT06754215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: Participate in focus group
Study NCT06754215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in semi-structured interview
Study NCT06754215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Participate in feasibility study of intervention components
Study NCT06754215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study NCT06753968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Right Hemicolectomy With Transrectal/transvaginal Specimen Extraction (NOSES)
Description: Transvaginal extraction, begins with the irrigation and disinfection of the vagina, followed by a transverse incision in the posterior fornix. The assistant then utilizes oval forceps to carefully extract the specimen bag through the incision, which is subsequently closed with continuous full-thickness sutures, using barbed sutures to ensure secure closure. Similarly, transrectal extraction begins with irrigation of the rectum using a dilute iodine solution, followed by a longitudinal incision along the anterior wall of the upper rectum. The specimen, along with the protective sleeve, is then removed using oval forceps, and the incision is closed with a continuous full-layer running suture once the specimen has been completely extracted.
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6213
Description: MK-6213 160 mg for 4 weeks.
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin calcium
Description: atorvastatin calcium 20mg for 4 weeks.
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: atorvastatin calcium 20mg for 4 weeks.
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for MK-6312 160 mg
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-6312 160 mg
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin 20 mg
Study NCT00687271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Atorvastatin 20 mg
Study NCT02968173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palivizumab
Description: Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
Study NCT01073813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 100mg twice daily
Study NCT06753968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally laparoscopic right hemicolectomy (TLRH)
Description: Totally laparoscopic right hemicolectomy (TLRH), which involves performing intracorporeal anastomosis and specimen extraction through a small abdominal incision, further enhances the benefits of minimally invasive surgery. In the TLRH group, following the stapled side-to-side anastomosis, a small horizontal incision is made about 2 to 3 cm above the symphysis pubis, at the junction of the pubic hairline, to allow for specimen removal.
Study NCT03575052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
Study NCT03575052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth (provided as two placebo tablets)
Study NCT02423395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orphenadrine
Description: Orphenadrine in muscle cramps in cirrhotic patients
Study NCT02423395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcium in muscle cramps in cirrhotic patients
Study NCT03938350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) Skills Training
Description: Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation. The sessions will be delivered virtually via a HIPAA-compliant video platform.
Study NCT02589132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile-Thrive application
Description: Families receive standard of care plus the Mobile-Thrive application
Study NCT02695550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-707
Study NCT04124601 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Chemoradiotherapy
Description: Capecitabine tablet with fractionated radiotherapy
Study NCT04124601 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Capecitabine tablet with fractionated radiotherapy
Study NCT04124601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion
Study NCT04124601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Infusion
Study NCT04699318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B
Description: To release the pediatric hypospadias using Double Dartos Tubularized incised plate (TIP) Urethroplasty
Study NCT04699318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: To release the pediatric hypospadias using Single Dartos Tubularized incised plate (TIP) Urethroplasty
Study NCT00890370 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway clearance technique
Study NCT00246129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath
Description: Monoclonal antibody induction therapy
Study NCT00246129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Monoclonal antibody induction therapy
Study NCT02704026 — intervention group
Intervention type: OTHER
Intervention: Assesment of nutritional status and body composition
Description: At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
Study NCT03740737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed.
Study NCT03740737 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Study NCT03261713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
Study NCT03261713 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
Study NCT02380885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: psychosocial group intervention
Study NCT02380885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAFT
Description: psychosocial group intervention
Study NCT00702338 — intervention group
Intervention type: DRUG
Intervention: corifollitropin alfa
Description: SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
Study NCT00702338 — intervention group
Intervention type: BIOLOGICAL
Intervention: recombinant Follicle Stimulating Hormone (recFSH)
Description: Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
Study NCT00702338 — intervention group
Intervention type: BIOLOGICAL
Intervention: human Chorion Gonadotropin (hCG)
Description: Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
Study NCT00702338 — intervention group
Intervention type: BIOLOGICAL
Intervention: hCG Bolus injection
Description: Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
Study NCT00084409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Given orally
Study NCT00084409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01142388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT03059745 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
Study NCT00516672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib oral tablet
Study NCT00516672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib oral tablet
Study NCT01219426 — intervention group
Intervention type: OTHER
Intervention: Filling of three questionnaires
Description: The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
Study NCT00072280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given Slow intravenous (IV) push over 1-5 minutes, dose \< 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
Study NCT00072280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
Study NCT00072280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
Study NCT00072280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
Study NCT00072280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
Study NCT00072280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Description: Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections.
Study NCT00072280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MESNA (mercaptoethane sulfonate)
Description: Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
Study NCT00072280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
Study NCT01142388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03763929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans-Sodium Crocetinate
Description: In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
Study NCT03763929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
Study NCT02612623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant tablets administered by mouth twice daily for 8 weeks
Study NCT02612623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
Study NCT03598023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cytal® Burn Matrix
Description: Cytal® Burn Matrix
Study NCT03598023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-Derm® Porcine Xenograft
Description: EZ-Derm® Porcine Xenograft
Study NCT02960711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]
Study NCT02960711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ludipress, mg stereate, micronized hydrated silica, talcum
Description: Tablet
Study NCT05750602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIMICOL
Description: Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
Study NCT05750602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
Study NCT03267082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic management of perforated appendicitis
Description: 1. Insertion of Ports~2. Exposure of the Appendix~3. peritoneal toilet and aspiration of pus after abdominal exposure~4. Isolation of Mesoappendicular Artery~5. Clipping and Dividing of the Artery~6. Application of 3 x Endoloops~7. Division of the Appendix~8. Retrieval of the Appendix in an Endobag
Study NCT01448330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0911 / clopidogrel, aspirin
Description: combination tablet vs coadministration
Study NCT01448330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0911 / clopidogrel, aspirin
Description: combination tablet vs coadministration
Study NCT03656692 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acthar Gel
Description: Acthar gel for subcutaneous injection 80 units per mL (40 units per 0.5 mL)
Study NCT03213002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at 1500 mg/m2
Study NCT03213002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide at 150 mg/m2 - 200 mg/m2
Study NCT01142388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01142388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01386385 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-conformal RT
Study NCT00468481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)